Bionexus Gene LabBGLC
13F holders, Q3 2025 (September 30)2holders +1
1new positions
0sold out
$5.47avg. 13F price*
At the end of Q3 2025, 2 institutions reported holding Bionexus Gene Lab Corp. (BGLC) in their 13F filings, up 1 from Q2 2025. 1 opened new positions and 0 sold out. The largest holders were DRW Securities, LLC ($80K) and UBS Group AG ($42K).
- Company
- Bionexus Gene Lab Corp.
- CUSIP
- 090628306
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $80K |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 14,651 shares bought and 1,936 shares sold, net +12,715 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| DRW Securities, LLC | 0.00% | New | 14,651 | $80K |
| UBS Group AG | 0.00% | Reduce -20.3% | 7,626 | $42K |
"% of holder's portfolio" is BGLC's weight in each manager's 13F, not the share of Bionexus Gene Lab Corp. the manager owns.